Promino Nutritional Sciences Inc. (MUSLF)
| Previous close | 0.0350 |
| Open | 0.0323 |
| Bid | 0.0350 x 0 |
| Ask | 0.0460 x 0 |
| Day's range | 0.0323 - 0.0323 |
| 52-week range | 0.0114 - 0.3690 |
| Volume | |
| Avg. volume | 18,311 |
| Market cap | 2.982M |
| Beta (5Y monthly) | 2.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings date | 29 Nov 2024 - 04 Dec 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePromino Nutritional Sciences Inc. Announces Promino™ and Rejuvenate Muscle Activator™ Brands Debut on The Kroger Co.'s vitacost.com
Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X)( the "Company" or "Promino")(www.drinkpromino.com) today announced that the all-new Promino™ and Rejuvenate Muscle Activator™ products released in July are now featured on www.vitacost.com, the Boca Raton, Florida-based e-commerce retailer owned by The Kroger Co.
PR NewswirePROMINO NUTRITIONAL SCIENCES PROVIDES CORPORATE UPDATE
Promino Nutritional Sciences, Inc. (CSE: MUS) (OTC: MUSLF) (FRANKFURT: 93X) ( the "Company" or "Promino") (www.drinkpromino.com) today provides a corporate update on significant milestones achieved in the last nine months.
PR NewswirePromino Nutritional Sciences and Dr. Patrick Gunning to Begin Preclinical Studies Focused on Targeted Nutritional Supplementation for Cancer Patients
Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FRANKFURT: 93X) (the "Company" or "Promino") is pleased to announce it has retained award winning PhD Dr. Patrick Gunning to assess preclinical studies conducted on its patented formulation's mitigation of muscle loss in cancer patients. Dr. Gunning will be joining the Company as a special advisor on various preclinical studies over the next 12 months.
